Clinical Trials

Home/Clinical Trials

A ‘Clinical Trial of One’

October's LRG newsletter features artist Douglas Morgan, who found himself with a rare GIST mutation and no treatment options until an innovative oncologist and a compassionate gesture by a pharmaceutical company gave him a chance to receive a unique treatment.

By |2019-11-08T11:08:49-05:00October 29th, 2019|Clinical Trials, Member Stories, News, Newsletter|

LRG Webcast Series: Updates on the Temozolomide Trial

Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.

By |2019-11-26T12:37:19-05:00September 16th, 2019|Clinical Trials, News, Webcast|

Update on a New Clinical Trial Offered to Eligible GIST Patients

The INTRIGUE study is a Phase 3 clinical trial testing the investigational drug ripretinib (DCC-2618) for patients living with GIST that are no longer on imatinib due to progression or intolerance.

By |2019-08-21T11:40:48-04:00June 20th, 2019|Clinical Trials, News, Newsletter|

Life Fest 2 Pharma Panel: Addressing Key Mechanisms of Tumor Drug Resistance

Pharma Panel: Overview of Promising Trials for GIST "Addressing Key Mechanisms of Tumor Drug Resistance" Deciphera Pharmaceuticals view all Life Fest 2018 Videos

By |2019-03-20T09:37:21-04:00September 18th, 2018|Clinical Trials, Events, Video|

GIST Updates from the ASCO Annual Meeting 2018

Executive Director, Norman Scherzer, and Real World Evidence Data Scientist, Dr. Yu Wang, of the Life Raft Group recently attended the ASCO (American Society of Clinical Oncologists) 2018 meeting in Chicago. Dr. Wang describes [...]

By |2018-10-29T13:43:20-04:00June 18th, 2018|Clinical Trials, News, Research|

Deciphera Pharmaceuticals Announces the Start of Phase 3 Clinical Trial with DCC-2618 in GIST

On January 4th, 2018 Deciphera Pharmaceuticals, Inc, announced the start of the Phase 3 INVICTUS trial. This randomized trial is for 4th line GIST patients that have failed (or are intolerant) the [...]

By |2018-10-29T13:46:27-04:00January 9th, 2018|Clinical Trials, News|